Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice

Abstract

BACKGROUND: Acute coronary syndrome (ACS) as a clinical manifestation of coronary artery disease
(CAD) remains a significant cause of mortality and morbidity, as reported worldwide annually. The
second generation of drug-eluting stents (DES) is a gold standard in percutaneous interventions in ACS
patients however, permanent caging of the vessel with metallic DES has some drawbacks. Bioresorbable
vascular scaffolds (BRS) were designed as a temporal vessel-supporting technology allowing for anatomical
and functional restoration. Nevertheless, following the initial encouraging reports, numerous
concerns about the safety of BRS occurred.
METHODS: In this study, a 1-year performance of 193 patients with magnesium BRS — Magmaris
(Biotronik, Berlin, Germany) was evaluated in comparison to 160 patients with polymer BRS —
Absorb (Abbott-Vascular, Chicago, USA) in the non-ST-segment elevation-ACS setting.
RESULTS: The Magmaris, when compared to Absorb showed a significantly lower rate of primary
endpoint (death from cardiac causes, myocardial infarction, stent thrombosis) as well as target lesion
failure in 30-day and 1 year follow-up. In the Absorb group, a significantly higher rate of stent thrombosis
was observed.
CONCLUSIONS: Data from the present study suggests encouraging safety a profile and more favorable
clinical outcomes of magnesium BRS in comparison to the polymer Absorb — BRS.